chufangao/CTO huggingface dataset:
Clinical trial NCT03508167: Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
Official title: National, Phase III, Monocentric, Randomized, Double-blind, Controlled, Parallel, to Evaluate the Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
Acronym: Delfos
Sponsor: Ache Laboratorios Farmaceuticos S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study design will be reformulated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2020-10-31
Completion date: 2020-11-30
Clinical trial NCT05102162: BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
Official title: Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low recruitment.
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-17
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Baseline population: Each participant that was unenrolled from the study was assessed to determine if the data could be used in the final analysis. 17 participants completed the study and we unenrolled 18 participants. However, we were able to use the data from 1 participant in the final analysis
Limitations and caveats: * Early termination leading to a small sample size and under-powered study.~* Repeat positive cultures may have been due to colonization and not active infection, especially in participants demonstrating clinical cure prior to repeat cultures.~* This study used MICs, which are generally accepted to have variability with repeat assessments, potentially up to 200% or more.
Plan to share individual participant data: NO
Clinical trial NCT04753606: Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Official title: A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy
Acronym: ROSE
Sponsor: NewAmsterdam Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-02-18
Primary completion date: 2021-05-24
Completion date: 2021-08-30
Baseline population: Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.
Plan to share individual participant data: NO
Clinical trial NCT04732221: A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
Official title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 168.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-05-19
Primary completion date: 2024-01-04
Completion date: 2024-07-02
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05014360: A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
Official title: A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-10
Primary completion date: 2023-02-15
Completion date: 2023-02-15
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03015519: A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
Official title: A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study did not start recruiting as albiglutide would have been withdrawn from the market prior to study end.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-08-14
Primary completion date: 2020-04-20
Completion date: 2020-04-20
Clinical trial NCT04738136: Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
Official title: A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy Of S-1226 In Hospitalized Subjects With Moderate Severity Covid-19 Bronchiolitis/Pneumonia
Sponsor: SolAeroMed Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Sponsor Decision
Enrollment: 30.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-09-15
Primary completion date: 2021-10-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04935801: A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
Official title: naNO-DENGUE: A Phase I Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T-Cell Priming Peptide Vaccine Against Dengue Virus in Healthy Adults in Switzerland
Sponsor: Emergex Vaccines Holding Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 26.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-08-02
Primary completion date: 2022-03-11
Completion date: 2022-09-15
Plan to share individual participant data: YES
IPD sharing description: The Investigators will be involved in writing and/or reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study.~Apart from obvious flaws to the conduct of the study, which may preclude data publication, safety and efficacy data will be published under the supervision and authorization of PI and Sponsor.~Publication will include as much individual level data as possible to ensure reproducibility of results without compromising participant privacy.
IPD time frame: Within 12 months of study completion
IPD access criteria: Peer-reviewed publication
Clinical trial NCT04128891: Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
Official title: PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction
Acronym: PRISTINE-HF
Sponsor: Flinders University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Funding not approved
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-01
Primary completion date: 2020-02-01
Completion date: 2024-02-01
Clinical trial NCT04933916: Study of EMB-001 as a Potential Smoking Cessation Treatment
Official title: Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
Sponsor: Embera NeuroTherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-10
Primary completion date: 2023-04-01
Completion date: 2023-05-01
Plan to share individual participant data: NO
Clinical trial NCT03597009: A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
Official title: A Phase Ib/II Study of IV Nivolumab and Intrapleural Talimogene Laherparepvec for Patients With Malignant Pleural Effusion
Sponsor: UNC Lineberger Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: due to slow accrual and withdrawal of funding
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-06
Primary completion date: 2020-02-07
Completion date: 2020-02-12
Limitations and caveats: Study terminated early due to slow accrual and withdrawal of funding so only one participant was enrolled.
Clinical trial NCT03594955: First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
Official title: An Open-label, First-in-human, Dose Escalation Study of SAR440234 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), or High Risk Myelodysplasia (HR-MDS)
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-24
Primary completion date: 2021-02-06
Completion date: 2021-02-06
Baseline population: Analysis was performed on safety population which included all registered participants who had given their informed consent and had received at least 1 dose of SAR440234.
Limitations and caveats: Sponsor decided to prioritize development of other novel therapies with more innovative mechanisms of action for R/R AML and other cancers. Thus, decided to terminate the study and stopped enrollment in Dose Expansion Part.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03536390: A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD
Official title: A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The study was cancelled prior to the enrollment of any participants.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-19
Primary completion date: 2021-04-22
Completion date: 2021-04-22
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Clinical trial NCT05463393: Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients
Official title: Humulus Lupus Extract Rich in Xanthohumol Improves Clinical Course in Critically Ill COVID-19 Patients
Sponsor: Medical University of Lublin (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: SUSPENDED 
Why stopped: We are waiting for the additional founds.
Enrollment: 50.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-10-01
Primary completion date: 2022-01-30
Completion date: 2024-12-31
Clinical trial NCT04260360: Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
Official title: Phase 1 Trial Evaluating the Safety and Tolerability of NanoDoce® Intratumoral Injection in Subjects With Localized Renal Cell Carcinoma
Sponsor: NanOlogy, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Not initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-30
Primary completion date: 2022-06-30
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Official title: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study closed due to portfolio prioritization
Enrollment: 132.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-05-29
Primary completion date: 2023-12-01
Completion date: 2023-12-01
Clinical trial NCT03794583: Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Official title: An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Acronym: PERFECT OLE
Sponsor: United Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-21
Primary completion date: 2022-11-29
Completion date: 2022-11-29
Baseline population: Safety population included all participants who received at least 1 dose of inhaled treprostinil.
Limitations and caveats: Per sponsor decision, the study was terminated early.
Plan to share individual participant data: NO
Clinical trial NCT04450654: Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)
Official title: Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No Participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-31
Primary completion date: 2022-07-25
Completion date: 2022-07-25
Clinical trial NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Official title: A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 3.0
Start date: 2011-05-17
Primary completion date: 2023-08-29
Completion date: 2023-10-24
Limitations and caveats: AbbVie has decided to discontinue further subject enrollment in the OG09002 (Oxybutynin) study. This decision is not based on a safety or an efficacy signal; rather this decision was made because of a change in AbbVie's development.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03300921: A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Official title: A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-28
Primary completion date: 2020-08-30
Completion date: 2022-03-23
Clinical trial NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19
Official title: A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
Sponsor: Shanghai JunTop Biosciences Co., LTD (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Based on the current number of COVID-19 cases and the approval of COVID-19 treatment drugs , the research team is facing great challenges, and it is decided to terminate this study
Enrollment: 381.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-28
Primary completion date: 2023-03-23
Completion date: 2023-03-23
Plan to share individual participant data: UNDECIDED
IPD sharing description: Undecided
Clinical trial NCT06145399: A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
Official title: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging In Patients Advanced Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No accruals
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-10-24
Primary completion date: 2024-04-29
Completion date: 2024-04-29
Plan to share individual participant data: YES
IPD sharing description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT02575404: GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Official title: Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Sponsor: Providence Health & Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-05-16
Primary completion date: 2021-01-12
Completion date: 2022-10-10
Plan to share individual participant data: NO
Clinical trial NCT04535518: Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
Official title: Efficacy of Primary Treatment With Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease: a Multicenter, Open-label, Blinded-end Randomized Controlled Study.
Sponsor: Children's Hospital of Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-31
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT03321513: DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Official title: Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
Acronym: DRCR AC
Sponsor: Jaeb Center for Health Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 270.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-07
Primary completion date: 2021-12-22
Completion date: 2021-12-22
Baseline population: Units in Eyes
Plan to share individual participant data: NO
Clinical trial NCT05678257: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
Official title: A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer
Sponsor: NuCana plc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.
Enrollment: 182.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-04-18
Primary completion date: 2024-08-29
Completion date: 2024-08-29
Plan to share individual participant data: NO
Clinical trial NCT00112931: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
Official title: An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma
Sponsor: University College, London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 462.0 (ACTUAL)
Number of arms: 2.0
Start date: 2004-09-30
Primary completion date: 2014-03-31
Completion date: 2023-09-14
Plan to share individual participant data: UNDECIDED